Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines

Rieko Oyama, Mami Takahashi, Akihiko Yoshida, Marimu Sakumoto, Yoko Takai, Fusako Kito, Kumiko Shiozawa, Zhiwei Qiao, Yasuhito Arai, Tatsuhiro Shibata, Yoshihiro Araki, Makoto Endo, Akira Kawai, Tadashi Kondo

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

CIC-DUX4 sarcoma (CDS) is a group of rare, mesenchymal, small round cell tumours that harbour the unique CIC-DUX4 translocation, which causes aberrant gene expression. CDS exhibits an aggressive course and poor clinical outcome, thus novel therapeutic approaches are needed for CDS treatment. Although patient-derived cancer models are an essential modality to develop novel therapies, none currently exist for CDS. Thus, the present study successfully established CDS patient-derived xenografts and subsequently generated two CDS cell lines from the grafted tumours. Notably, xenografts were histologically similar to the original patient tumour, and the expression of typical biomarkers was confirmed in the xenografts and cell lines. Moreover, the xenograft tumours and cell lines displayed high Src kinase activities, as assessed by peptide-based tyrosine kinase array. Upon screening 119 FDA-approved anti-cancer drugs, we found that only actinomycine D and doxorubicin were effectively suppress the proliferation among the drugs for standard therapy for Ewing sarcoma. However, we identified molecular targeting reagents, such as bortezomib and crizotinib that markedly suppressed the growth of CDS cells. Our models will be useful modalities to develop novel therapeutic strategies against CDS.

Original languageEnglish
Pages (from-to)4712
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - Jul 5 2017

Fingerprint

Heterografts
Sarcoma
Cell Line
Tumor Cell Line
Neoplasms
Ewing's Sarcoma
src-Family Kinases
Therapeutics
Protein-Tyrosine Kinases
Doxorubicin
Biomarkers
Gene Expression
Drug Therapy
Peptides
Growth
Pharmaceutical Preparations

Cite this

Oyama, R., Takahashi, M., Yoshida, A., Sakumoto, M., Takai, Y., Kito, F., ... Kondo, T. (2017). Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. Scientific Reports, 7(1), 4712. https://doi.org/10.1038/s41598-017-04967-0

Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. / Oyama, Rieko; Takahashi, Mami; Yoshida, Akihiko; Sakumoto, Marimu; Takai, Yoko; Kito, Fusako; Shiozawa, Kumiko; Qiao, Zhiwei; Arai, Yasuhito; Shibata, Tatsuhiro; Araki, Yoshihiro; Endo, Makoto; Kawai, Akira; Kondo, Tadashi.

In: Scientific Reports, Vol. 7, No. 1, 05.07.2017, p. 4712.

Research output: Contribution to journalArticle

Oyama, R, Takahashi, M, Yoshida, A, Sakumoto, M, Takai, Y, Kito, F, Shiozawa, K, Qiao, Z, Arai, Y, Shibata, T, Araki, Y, Endo, M, Kawai, A & Kondo, T 2017, 'Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines', Scientific Reports, vol. 7, no. 1, pp. 4712. https://doi.org/10.1038/s41598-017-04967-0
Oyama R, Takahashi M, Yoshida A, Sakumoto M, Takai Y, Kito F et al. Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. Scientific Reports. 2017 Jul 5;7(1):4712. https://doi.org/10.1038/s41598-017-04967-0
Oyama, Rieko ; Takahashi, Mami ; Yoshida, Akihiko ; Sakumoto, Marimu ; Takai, Yoko ; Kito, Fusako ; Shiozawa, Kumiko ; Qiao, Zhiwei ; Arai, Yasuhito ; Shibata, Tatsuhiro ; Araki, Yoshihiro ; Endo, Makoto ; Kawai, Akira ; Kondo, Tadashi. / Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines. In: Scientific Reports. 2017 ; Vol. 7, No. 1. pp. 4712.
@article{f06b0b852ba0445c80a9ab9a1003685d,
title = "Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines",
abstract = "CIC-DUX4 sarcoma (CDS) is a group of rare, mesenchymal, small round cell tumours that harbour the unique CIC-DUX4 translocation, which causes aberrant gene expression. CDS exhibits an aggressive course and poor clinical outcome, thus novel therapeutic approaches are needed for CDS treatment. Although patient-derived cancer models are an essential modality to develop novel therapies, none currently exist for CDS. Thus, the present study successfully established CDS patient-derived xenografts and subsequently generated two CDS cell lines from the grafted tumours. Notably, xenografts were histologically similar to the original patient tumour, and the expression of typical biomarkers was confirmed in the xenografts and cell lines. Moreover, the xenograft tumours and cell lines displayed high Src kinase activities, as assessed by peptide-based tyrosine kinase array. Upon screening 119 FDA-approved anti-cancer drugs, we found that only actinomycine D and doxorubicin were effectively suppress the proliferation among the drugs for standard therapy for Ewing sarcoma. However, we identified molecular targeting reagents, such as bortezomib and crizotinib that markedly suppressed the growth of CDS cells. Our models will be useful modalities to develop novel therapeutic strategies against CDS.",
author = "Rieko Oyama and Mami Takahashi and Akihiko Yoshida and Marimu Sakumoto and Yoko Takai and Fusako Kito and Kumiko Shiozawa and Zhiwei Qiao and Yasuhito Arai and Tatsuhiro Shibata and Yoshihiro Araki and Makoto Endo and Akira Kawai and Tadashi Kondo",
year = "2017",
month = "7",
day = "5",
doi = "10.1038/s41598-017-04967-0",
language = "English",
volume = "7",
pages = "4712",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Generation of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines

AU - Oyama, Rieko

AU - Takahashi, Mami

AU - Yoshida, Akihiko

AU - Sakumoto, Marimu

AU - Takai, Yoko

AU - Kito, Fusako

AU - Shiozawa, Kumiko

AU - Qiao, Zhiwei

AU - Arai, Yasuhito

AU - Shibata, Tatsuhiro

AU - Araki, Yoshihiro

AU - Endo, Makoto

AU - Kawai, Akira

AU - Kondo, Tadashi

PY - 2017/7/5

Y1 - 2017/7/5

N2 - CIC-DUX4 sarcoma (CDS) is a group of rare, mesenchymal, small round cell tumours that harbour the unique CIC-DUX4 translocation, which causes aberrant gene expression. CDS exhibits an aggressive course and poor clinical outcome, thus novel therapeutic approaches are needed for CDS treatment. Although patient-derived cancer models are an essential modality to develop novel therapies, none currently exist for CDS. Thus, the present study successfully established CDS patient-derived xenografts and subsequently generated two CDS cell lines from the grafted tumours. Notably, xenografts were histologically similar to the original patient tumour, and the expression of typical biomarkers was confirmed in the xenografts and cell lines. Moreover, the xenograft tumours and cell lines displayed high Src kinase activities, as assessed by peptide-based tyrosine kinase array. Upon screening 119 FDA-approved anti-cancer drugs, we found that only actinomycine D and doxorubicin were effectively suppress the proliferation among the drugs for standard therapy for Ewing sarcoma. However, we identified molecular targeting reagents, such as bortezomib and crizotinib that markedly suppressed the growth of CDS cells. Our models will be useful modalities to develop novel therapeutic strategies against CDS.

AB - CIC-DUX4 sarcoma (CDS) is a group of rare, mesenchymal, small round cell tumours that harbour the unique CIC-DUX4 translocation, which causes aberrant gene expression. CDS exhibits an aggressive course and poor clinical outcome, thus novel therapeutic approaches are needed for CDS treatment. Although patient-derived cancer models are an essential modality to develop novel therapies, none currently exist for CDS. Thus, the present study successfully established CDS patient-derived xenografts and subsequently generated two CDS cell lines from the grafted tumours. Notably, xenografts were histologically similar to the original patient tumour, and the expression of typical biomarkers was confirmed in the xenografts and cell lines. Moreover, the xenograft tumours and cell lines displayed high Src kinase activities, as assessed by peptide-based tyrosine kinase array. Upon screening 119 FDA-approved anti-cancer drugs, we found that only actinomycine D and doxorubicin were effectively suppress the proliferation among the drugs for standard therapy for Ewing sarcoma. However, we identified molecular targeting reagents, such as bortezomib and crizotinib that markedly suppressed the growth of CDS cells. Our models will be useful modalities to develop novel therapeutic strategies against CDS.

U2 - 10.1038/s41598-017-04967-0

DO - 10.1038/s41598-017-04967-0

M3 - Article

C2 - 28680140

VL - 7

SP - 4712

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

ER -